| Ascension
Health Ventures Ascension Health Ventures, LLC (AHV) was launched in 2001 as a subsidiary of Ascension Health, the largest nonprofit Catholic healthcare system in the United States. Through AHV, Ascension Health provides strategic venture funding to companies that offer healthcare-related products, services or technologies that represent potential service breakthroughs for Ascension Health’s hospitals and health facilities and contribute to the transformation of healthcare. Ascension Health Ventures also partners with select healthcare venture capital funds to achieve portfolio diversification. In order to be considered for an AHV investment, companies and other venture funds must be consistent with Ascension Health’s Mission, Vision and Values. The products or services of the portfolio companies must also provide clinical, operational and/or financial value to the System. Ascension Health Ventures targets later-stage development companies that have clear momentum. Key attributes of an opportunity include experienced management, fully-developed products or services with an existing customer base, formalized business plans with documented value propositions, prior financing and identified exit strategies. |
 |
| Advanced
Technology Ventures Founded in 1979, Advanced Technology Ventures (ATV) is a bi-coastal venture capital firm with more than $1.5 billion in capital under management. We work closely with entrepreneurial teams in several technology markets, including communications, IT infrastructure, software and services, and healthcare technologies, to build emerging-growth business ventures into market leaders. With more than 20 years of experience, ATV has a proven track record of success in helping to build strong, sustainable business enterprises. What Sets ATV Apart:
Successful Track Records: Over the years, ATV has a proven history in supporting over 30 companies from inception to IPO or acquisition, representing billions of dollars in market value. Examples include Accord Networks, Actel, Berkeley Networks, Credence Systems, Cytyc, DataSage (Vignette), Docent, Epigram (Broadcom), Novoste, Seagull Software and WebLine Communications (Cisco). |
| Advent
International Advent International is one of the world’s largest private equity firms with $6 billion in cumulative capital raised* and offices in 13 countries. We are unique. No other private equity firm has our combination of industry expertise, international resources and local market knowledge. Since our founding in 1984, we have invested in over 500 companies in 35 countries and have helped businesses raise $10 billion through public equity and debt offerings. These include 128 IPOs on major stock exchanges worldwide. We apply our wealth of experience, resources and expertise to help build businesses of significant value around the globe. |
| Atlas
Venture Atlas Venture is the leading international early-stage venture capital firm, investing in communications, information technology and life sciences companies. With investing offices in Boston, London, Munich and Paris, Atlas Venture divides its investments between the United States and Europe. Founded in 1980, Atlas Venture has organized six international funds, and currently manages $2.1 billion in committed capital. The Atlas Venture investment team is comprised of seasoned operating executives and career venture capitalists who have been deeply involved in the formation and development of more than 300 companies worldwide. For more information about Atlas Venture, go to www.atlasventure.com. |
 |
| Banc
of America Securities LLC Banc of America Securities LLC ("BAS"), a subsidiary of Bank of America Corporation, is a full-service U.S. investment bank and brokerage firm with principal offices in San Francisco, New York, and Charlotte. Together with its U.K. affiliate, Banc of America Securities Limited ("BASL"), the firm delivers capital raising, financial advisory and risk management solutions, bulge-bracket trading and global distribution services, and objective research on global markets and growth sectors to corporations, institutional investors, financial institutions and government entities. BAS is a member of the following exchanges: New York Stock Exchange (NYSE), National Association of Securities Dealers (NASD) American Stock Exchange (AMEX), Boston Stock Exchange (BSE), Chicago Board of Options Exchange (CBOE), Chicago Stock Exchange CHX), Cincinnati Stock (CSE), International Securities Exchange (ISE), Pacific Stock Exchange (PSE), Philadelphia Stock Exchange (PHLX) and is registered as an international dealer with the Ontario Securities Commission. BASL is a UK authorized credit institution, regulated by the FSA under the Financial Services and Markets Act 2000 in the UK. It is a company incorporated with limited liability in England and Wales with registered number 01009248 and is a wholly owned subsidiary of Bank of America, National Association ("BANA"), headquartered in Charlotte, North Carolina, USA. BASL is a member of the following exchanges: London Stock Exchange, Euronext Paris, Euronext Amsterdam, and Borsa Italiana. BAS and BASL are subsidiaries respectively of Bank of America Corporation ("BAC"). BAC is one of the world’s leading financial services companies, with more than 140,000 associates, offices in 32 countries and client solutions spanning 190 countries. The company’s stock (ticker: BAC) is listed on the New York, Pacific and London stock exchanges, and certain shares are listed on the Tokyo Stock Exchange. For more information about BAC’s corporate and institutional capabilities, visit www.bofa.com. For information about BAC’s extensive consumer banking franchise, visit www.bankofamerica.com. |
| Beyond
Genomics Founded in 2000, Beyond Genomics is an emerging biotechnology company that applies its proprietary Systems Biology platforms to develop novel therapeutics and biomarkers (BioSystem Markers™) . Current approaches such as genomics and proteomics focus on one aspect of biological systems at a time. Rather than ignoring or over-simplifying the inherent complexity of biological processes that underlie human diseases or that govern drug responses, Beyond Genomics has pioneered the creation of Molecular Phenotypes™ to enable biological research at the systems level. Molecular Phenotyping™ involves measuring complex biological samples, including simultaneously measuring transcripts, proteins and metabolites, and integrating these data sets with clinical information. Tracking changes in Molecular Phenotypes™ can improve multiple aspects of pharmaceutical discovery and development, including drug safety and efficacy, drug response, and the etiology of disease. BG’s Systems Biology platform integrates state-of-the-art technologies in proteomics, metabolomics, and bioinformatics. The company has also developed a proprietary BioSystematics™ data integration and knowledge management platform that generates connections, correlations, and relationships among thousands of measurable molecular components. |
| BioEnterprise
Asia BioEnterprise Asia is an Asia-Pacific life science technology management company. The company operates 3 complementary and synergistic businesses:
|
| Biotech
Consortium India Ltd Biotech Consortium India Ltd (BCIL), a company promoted by the Department of Biotechnology (DBT), Government of India and the all India financial institutions and corporate sector as the share holders, works for accelerated development and commercialization of biotechnology in India. For this purpose, it brings together industry and R & D institutions to facilitate translation of research into commercial ventures, provides consultancy to industry, government and international organizations to take forward biotechnology activities and creates awareness throughout the nation by information dissemination on significant current developments in the area. During the last ten years, the company has transferred many key technologies including diagnostics for HIV 1 and 2, Alphafetoprotein, Dengue, Japanese encephalitis and Hepatitis A and recombinant anthrax vaccine. It has provided consultancy assistance to more than 150 clients so far by preparing diversification plans, feasibility reports, project reports, market surveys and sectoral studies. It has also developed business plans for setting up Biotechnology Parks and Centres of Excellence in Biotechnology for many state governments and other development agencies. In recognition of its contributions, the company
was honoured with a special national award on Biotech Product and
Process Development and Commercialization in 2001. |
| Boston
Millennia Partners Boston Millennia Partners has a long and successful history of venture capital investing on a national scope. Our Core Company Investment Strategy, combined with our international network of relationships and our deep industry expertise, sets us apart and enables us to add value to our portfolio companies. We look for investment opportunities within four
high growth industries: We seek to partner with entrepreneurs who share our goal of building enduring, large-scale businesses that result in personal fulfillment and superior financial returns. Over the past twenty years, we have developed an investment approach that centers on active participation with our portfolio companies. Our goal is to be valuable and effective investors, while at the same time establishing productive relationships with our business partners that create long-term value. For more information, see our “What We Look For” section. Our investing philosophy is guided by our Core Company Investment Strategy, which accelerates the growth of a company through strategic consolidation within an industry. By following a targeted merger and acquisitions plan, a core portfolio company can quickly increase its scale and broaden the scope of its product and service offerings. The result is a company that replicates a proven business model around an existing core platform to build a large, high-growth enterprise. Within the past twenty years, core companies in our portfolio have completed over 160 strategic acquisitions. The growth and success of our portfolio companies have, in turn, allowed us to grow and expand our capital base to over $700 million. As our firm has grown, we have built a worldwide network. Investors from over a dozen countries have entrusted us to manage capital on their behalf. |
|
| Burrill
& Company Burrill & Company is a life sciences merchant bank focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses) with over $500 million under management. Burrill's technical and venture investing competence spans the entire spectrum of life sciences. The expertise of the firm's investment team, strategic partners and Advisory Boards is unparalleled in depth and breadth. In addition, Burrill is a leader in life science strategic partnering, an invaluable practice to build value in portfolio companies and to accelerate their growth and development. Burrill is also the sponsor and facilitator of three leading annual industry conferences and publishes the seminal annual report on the state of the biotechnology industry. This combination of resources and capabilities has helped Burrill develop a unique and highly effective platform for finding and making outstanding life science investments. |
|
| CDP
Capital – Technology Ventures Founded in 1995 as a subsidiary of the Caisse de dépôt et placement du Québec (CDP), CDP Capital - Technology Ventures (formerly CDP Sofinov), is a technology venture capital (VC) firm with an established presence in North America and, more recently, in Europe. CDP Capital - Technology Ventures assets under management have a market value of CDN$1.6 billion. Since its inception, it has invested in more than 160 privately owned technology companies in the following investment sectors: Biotechnology and Life Sciences, Information Technologies and Industrial Technologies. Mission An expert team CDP Capital |
| China
Chipscreen Biosciences Chipscreen Biosciences Ltd, established on March
21, 2001 in Shenzhen with initial seed-capital of $5.8 million US
dollars from investors across Asia, is a drug discovery company
specialized in novel small molecule therapeutics. Chipscreen has
developed a proprietary chemical genomics approach to accelerate
the discovery of new medicines from its collections of natural products,
traditional medicines, and synthetic chemical libraries. Central
to its drug discovery platform is the company's capability of integrating
in silico design, chemistry, unique parallel multi-targets high
throughput screening, global gene expression profiling, and informatics
to rapidly and effectively advance the drug discovery process. Members of the core team have published more than 200 peer-reviewed papers in related scientific journals including Nature, Science, Nature Medicine and Nature Biotechnology. The team has also published 4 books and has been awarded more than 20 international patents in the areas of biochips and novel small molecule therapeutics. They have identified 4 novel compounds that have entered FDA- and EMEA-approved clinical trials and have developed 6 biological research products that are being sold worldwide Chipscreen's Core Advantages: |
 |
| Flagship
Ventures Flagship Ventures is an early-stage venture capital firm focused on creating, financing, and building companies in the life science, information technology and communications sectors. Flagship’s team of 23 professionals is among the most experienced in the industry and represents a balance of venture capital, corporate executive, and entrepreneurship expertise. The firm was founded in 1999 and manages over $600 million on behalf of its institutional and corporate investors. Headquartered in Cambridge, MA, Flagship Ventures has been one of the most active early stage firms during the last three-year, post-bubble period and has developed a portfolio of over 40 high potential ventures. For further information please visit www.flagshipventures.com. |
 |
| Friedman,
Billings, Ramsey Group, Inc. R. Nelson Campbell, Senior Vice President, Life Sciences Investment Banking Friedman, Billings, Ramsey Group, Inc. provides investment banking, institutional brokerage, asset management, and private client services through its operating subsidiaries and invests in mortgage backed securities and merchant banking opportunities. FBR focuses capital and financial expertise on six industry sectors: financial services, real estate, technology, healthcare, energy and diversified industrials. We believe that FBR occupies a unique position in the capital markets. From our roots as a research boutique, we have grown to a top 10 ranked national investment bank. Our research, institutional brokerage and investment
banking services have placed us, with the Wall Street bulge bracket,
among the top 10 lead-managed equity underwriters* and among the
leading research-driven national brokerages, in the United States.
Our process combines our deep understanding of individual businesses in the context of their industries, with our significant experience in the capital markets. This, along with our intelligent institutional distribution, has enabled us to raise billions of dollars of capital as a lead-managing underwriter, including in transactions in excess of $500 million in size. FBR, headquartered in the Washington, D.C. metropolitan area, with offices in Arlington and Bethesda, also has offices in Atlanta, Boston, Charlotte, Chicago, Cleveland, Denver, Irvine, London, New York, Portland, San Francisco, Seattle, and Vienna. FBR has elected REIT status for tax purposes. For more information, see www.fbr.com. Mailing address: Five Walpole Street, Norwood, Massachusetts 02062. Telephone: 781-762-9782; Fax: 781-769-9782. |
| Genzyme
Corporation Founded in 1981, Genzyme today is one of the largest and most well established biotechnology companies in the world. With more than 25 major products and services marketed in over 60 countries, Genzyme is a global leader in the effort to develop and apply the most advanced capabilities in biotechnology to address a range of unmet medical needs. Genzyme-sponsored research and development has led to the introduction of new treatments for many serious health problems, from rare and debilitating genetic diseases to renal disease, orthopaedic injuries and the adverse effects of hypothyroidism. Building on more than two decades of growth and success, the company’s international R & D team and state-of-the art bioengineering and manufacturing facilities are continually at work identifying new opportunities to meet the health care challenges of the future. With headquarters in Cambridge, Massachusetts, Genzyme has approximately 5,500 employees working in 40 countries and annual revenues of more than $1 billion. Under the umbrella of Genzyme Corporation, the company is divided into three divisions, each representing a major focus of the health care market in research, product development, and patient care. |
 |
| Global
Life Science Ventures Global Life Science Ventures (GLSV) is an independent
venture capital firm dedicated exclusively to the life science industry.
With offices in Germany, Switzerland and the UK, GLSV focuses on
investments in early to late stage life science companies throughout
Europe and the U.S.. Its predecessor fund Global Life Science L.P.
advised by Life Science Ventures GmbH was founded in 1996 and raised
€ 66 million. GLSV II was launched in mid 2001 and raised €143million. Alliances: We have alliances with two US venture capital funds, Oxford Bioscience Partners and TechAMP of A.M. Pappas & Associates. In addition, we pro-actively build strong investment syndicates with other leading international VC funds for each investment. |
 |
Global
Markets Capital Group, LLC Global Markets Capital Group, LLC is an independent
investment banking firm providing innovative strategic advisory
services and mergers and acquisitions expertise globally to public
and private companies. Through its advisory roles and its network
of global companies active in Europe, Asia, Australia and the US,
the firm has assisted numerous international life sciences and emerging
technology companies in achieving their strategic goals. The firm
has extensive M&A experience, specializing on international
and cross-border transactions, including: To each engagement, GMCG, LLC brings independence, rigorous analysis, cultural understanding and local experience. It is this experience and application of our proven process that culminates in the closure of successful transactions in the best interests of our clients. A critical element in enabling European, Asian, and Australian companies to take advantage of strategic opportunities is our ability to access the US capital markets as a licensed NASD broker/dealer. |
HarbourVest
Partners, LLC HarbourVest Partners, LLC is a global private equity investment firm. It was founded in 1997 to assume the business of Hancock Venture Partners, Inc., which was formed in 1982. HarbourVest is 100%-owned by members of the investment team. HarbourVest invests in all types of private equity funds, including venture capital and leveraged buyout funds, and also directly in operating companies. HarbourVest currently manages investments in North America, South America, Europe, Asia, Australia and Africa. The Senior Managing Directors of HarbourVest Partners have been investing together since 1979, and all 16 Managing Directors have worked at HarbourVest or Hancock Venture Partners, Inc. for an average of more than 14 years. HarbourVest Partners is a limited liability company that was formed in January 1997 by the former management of Hancock Venture Partners, Inc. ("Hancock Venture Partners") to assume the business of Hancock Venture Partners. Hancock Venture Partners was founded in 1982 by the two Senior Managing Directors of HarbourVest to provide institutional investors with a vehicle through which to invest in venture capital and other private equity partnerships as well as directly into operating companies. The firm's clients include more than 200 pension funds, endowments, foundations, and financial institutions from the U.S., Europe, Canada, Australia, and Japan. During its 20-year history of investing, the HarbourVest team has committed $7.9 billion to 200 managers of private equity funds on a primary basis, completed $1.3 billion in 210 purchases of secondary partnership interests, and invested $1.9 billion directly in operating companies. Since 1982, the management of HarbourVest has formed six major investment programs to invest in the United States, the most recent being HarbourVest Partners VI, a $4.6 billion investment program formed in 1999 to invest in partnerships, buyout partnerships, and direct investment opportunities. This fund is currently in an active investment mode. The management team is also responsible for forming four investment programs focused exclusively on making private equity investments outside the United States. HarbourVest International Private Equity Partners IV was formed in 2002 with $2.8 billion of capital, including $2.425 billion for partnership investments and $375.0 million for direct investments. This fund is currently in an active investment mode. |
Harvard
Clinical Research Institute Harvard Clinical Research Institute (HCRI) is a joint venture of Harvard Medical School and its affiliated teaching hospitals, including Brigham & Women’s Hospital, Beth Israel Deaconess Medical Center and Massachusetts General Hospital. HCRI’s mission is to improve health and quality-of-life by collaborating with academic and industry partners to conduct high-quality clinical research in a professionally nurturing and world class academic environment. HCRI draws on the experience of having conducted over 100 medical device, pharmaceutical and biologic product trials for domestic and international clients. Successful management of cardiovascular, peripheral vascular, neurology and nephrology trials has made HCRI an industry-leading CRO. HCRI works with a team of Harvard thought-leaders to provide cutting-edge trial design and data analysis, utilizing the latest biostatistical methodologies. These individuals, most of whom have appointments at Harvard Medical School and are well-published in peer-reviewed journals, provide Sponsors with strategic planning and strong scientific insight. Driven by a skilled Project Management team, HCRI also provides turnkey Data Management to Sponsors seeking a unique academic-based CRO that is a leader in today’s global research environment. HCRI’s services include database build, data entry, data cleaning and a novel process for clinical event adjudication that is highly regarded by industry. HCRI’s staff of approximately 160 individuals brings tremendous depth and experience to the conduct of clinical research. Together, we seamlessly integrate world-class thought leadership with industry responsiveness. |
Harvard
Medical School The Office of Technology Licensing and Industry Sponsored Research (OTL) mission is to facilitate the transfer of inventions made by researchers at the Harvard Medical School and the Harvard School of Dental Medicine to the private sector for development of health care products that benefit the public. Towards this end, we also seek to promote and establish fruitful research collaborations with industry. |
Imperial
College Innovations Imperial Innovations (ICIL) is the wholly owned technology transfer company of Imperial College, London.It is one of the leading technology transfer offices in the UK and particularly differentiates itself by focusing on providing extensive “hands on” support to the process of creating new ventures and structuring innovative financing arrangements to support their development. Imperial Innovations has created over 50 technology-based ventures since 1997, of which approximately half have been in the biotech and medical devices field. Imperial Innovations draws on the leading research activities of Imperial College, which is consistently rated as one of the top research-oriented universities in the UK and includes one of Europe’s largest medical schools. Imperial College’s Faculty of Medicine has campuses on 6 major NHS hospital sites and works closely with the NHS in identifying and exploiting novel technologies, and works closely with the other faculties in developing cross-disciplinary initiatives in fields such as bioengineering, bioinformatics, research technologies and medical devices. |
Infinity
Pharmaceuticals Infinity Pharmaceuticals, Inc., founded in February 2001, is a drug discovery com-pany that is developing and integrating unique approaches and capabilities in synthetic chemistry, chemical genetics, informatics, and biological screening. The company is positioned to capitalize on the enormous opportunity resulting from the genomics revolution by providing pharmaceutically active and selective new drug candidates to a broad, expanded range of well-validated biological targets. Infinity is based on the scientific power of diversity-oriented organic synthesis, informat-ics, and chemical genetic screening of pathways and phenotypes. Novel chemistry accessed through diversity-oriented synthesis generates molecules active and selective against a broader range of targets, including those previously thought to be “non-druggable.” Chemical genetic screening strategies enable exploration of the entire range of possible drug targets in a non-biased manner. The efficient integration of these two technologies, in combination with advanced informatics and automation, yields expanded pools of both validated drug targets and active drug candidates. Infinity Pharmaceuticals, Inc. |
INSTITUT
PASTEUR – Paris, France Established: 1887 The INSTITUT PASTEUR developement team operates with the goal of licensing new technologies to industry in major fields including: therapeutics, immunotherapy, cardiovascular, neurobiology, diagnostics, vaccines, cancer, genomics, proteomics, bioinformatics, microarray, gene therapy, agriculture, veterinary, biological material (transgenic mice, strains, hybridomas, antibodies). The INSTITUT PASTEUR, a private Institute dedicated
to Research and Public Health, was created in 1887 by Louis Pasteur.
Nowadays 2,700 staff and scientists are working on the campus in
Paris. 110 Research units, 10 WHO Collaborating centers and one
P4 laboratory are the essential resources of the Institute to conduct
a high quality Research focused on: The INSTITUT PASTEUR is a non profit private Institute and about 50 employees participate to the Business Development activity. Based on a portfolio of 3,300 patents, the revenues from Licensing of Technologies (Vaccines, Diagnostics and Therapeutics) represent the major part of the Business development contribution which accounts for 39% (73 Millions Euros) of the total budget of the Institut Pasteur (188 Million Euros in 2002). Major collaborations with industry have been already established with: Aventis Pasteur, Bio-Rad, Glaxo Smith Kline, Roche, Bayer etc… The INSTITUT PASTEUR is nowadays increasingly licensing technologies, in the above mentioned fields, to start-up and Biotech companies. The INSTITUT PASTEUR has contributed to the creation of different start-up companies in its BioTop incubator : 1998 : Hybrigenics (1998); Diatos (1999) ; Cellectis (1999); PasteurMediavita (2000) ; Evologic (2000); Celogos (2001); Theraptosis (2001); BT Pharma (2001) ; 2002 : Biocortech (2002) ; 2003 : Anaconda (2003) . |
International
Finance Corporation The International Finance Corporation (IFC) promotes sustainable private sector investment in developing countries as a way to reduce poverty and improve people’s lives. IFC is a member of the World Bank Group and is headquartered in Washington, DC. It shares the primary objective of all World Bank Group institutions: to improve the quality of the lives of people in its developing member countries. IFC Mission Statement. Established in 1956, IFC is the largest multilateral source of loan and equity financing for private sector projects in the developing world. It promotes sustainable private sector development primarily by:
Ownership and Management The Board of Governors delegates many of its powers to the Board of Directors, which is composed of the Executive Directors of the IBRD, and which represents IFC’s member countries. The Board of Directors reviews all projects. The President of the World Bank Group , James D. Wolfensohn, also serves as IFC’s president. IFC’s Executive Vice President, Peter Woicke, is responsible for the overall management of day-to-day operations. Funding of IFC’s Activities IFC’s equity and quasi-equity investments are funded out of its net worth: the total of paid in capital and retained earnings. Strong shareholder support, triple-A ratings, and the substantial paid-in capital base have allowed IFC to raise funds for its lending activities on favorable terms in the international capital markets. |
 |
Massachusetts
Institute of Technology The mission of the Technology Licensing Office is to bring about, through technology licensing, commercial investment in the development of inventions and discoveries flowing from research at the Massachusetts Institute of Technology, Lincoln Laboratory, and the Whitehead Institute. It is through these investments-and the economic development and new products that follow from them – that university technology provides direct benefits to the public. We grant licenses of our patented and copyrighted inventions to existing and startup companies that demonstrate the technical and financial capabilities to develop our early-stage technology into commercially successful products. Exclusive licenses are common, and encourage investment through intellectual property protection for the licensee. The M.I.T. Technology Licensing Office is a fully integrated component of the Massachusetts Institute of Technology – one of the world’s leading research institutions in the sciences and engineering. Our office manages the transition between research results and licenses for the commercial development of products. At any one time we have four to five hundred patents pending, and about half our technologies are licensed before a patent issues . |
Merck
Research Laboratories Profile available shortly. |
Merrimack
Pharmaceuticals Merrimack Pharmaceuticals, Inc., is a biotechnology company focused on the discovery and development of drugs for the treatment of immunological and autoimmune diseases, many of which have only limited or problematic therapeutic options. The company_s proprietary _network biology_ approach to drug discovery combines next-generation proteomic technologies with an informed biological perspective to evaluate the complex protein pathways and cellular processes that cause disease. Merrimack believes it can address many of the inefficiencies in current discovery approaches and improve drug-target validation, increase quality lead identification and speed the development of novel, effective and safe therapeutics. Merrimack is a privately held company based in Cambridge, Massachusetts. For additional information, please visit www.merrimackpharma.com. |
Millennium
Pharmaceuticals, Inc. Millennium was founded in 1993 with a vision that still drives us today: to transcend the limits of medicine.sm We believe that by applying the methods of leading science to the art of drug discovery, we will develop breakthrough products that will fundamentally change the practice of medicine. Beginning in 1994, Millennium created more than 20 strategic alliances with leading pharmaceutical and biotechnology companies. These alliances provided Millennium with close to $2 billion of committed funding that we used to develop and enhance our pipeline. With an innovative, integrated science and technology platform, expertise in drug-target discovery, and industry-leading partnerships, the company was geared to prime the product pipeline. Through transformational mergers and acquisitions, Millennium continued to advance toward the goal of building a leading biopharmaceutical company. A merger with Leukosite in 1999 brought the company its first drug close to market, Campath® (alemtuzumab) Injection, and additional investigational drugs in clinical trials. In February 2002, a merger with COR Therapeutics — among the largest such mergers in the history of the biotech industry — helped to further solidify our standing as a leading biopharmaceutical company. In addition to creating a strong pipeline of novel therapeutics, the merger added cardiovascular research and drug development to the Company’s other key therapeutic areas: oncology and inflammation. The merger also brought INTEGRILIN® (eptifibatide) Injection, a market-leading intravenous anti-platelet drug for patients with severe cardiovascular diseases, into the Millennium fold. As Millennium celebrated its tenth anniversary in 2003, the company reached new heights. VELCADE® (bortezomib) for Injection was launched in May for the treatment of relapsed and refractory multiple myeloma. VELCADE — the first FDA approved proteasome inhibitor reached the market in record time and represents the first treatment in more than a decade to be approved for patients with multiple myeloma — a cancer of the blood. Today, Millennium has two leading products, proven commercial capabilities, and many product candidates in varying stages of development. We are continually evolving to ensure that our research and development efforts stay current with the demand for new diagnostic and therapeutic products that will make a genuine difference in patient’s lives. |
 |
Monument
Group Established in 1994, Monument Group is a specialized placement agent whose sole business is providing superior alternative investment opportunities to institutional investors. Each of the firm’s principals has extensive “buy-side” experience, either as consultants or investors. Since its formation, the firm has successfully undertaken transaction structuring and placement assignments for a variety of high-quality investment firms, encompassing a diverse range of alternative asset classes including venture capital, buyouts, distressed securities, special situations, oil & gas, mezzanine/subordinated debt, real estate and international private equity. |
 |
MPM
Capital MPM Capital is the world’s largest dedicated investor in life sciences. With committed capital under active management of more than $2.1 billion, MPM is uniquely structured to invest globally in healthcare innovation. In addition to its BioVentures family of venture capital funds, MPM invests in the public markets through its BioEquities hedge fund. Primarily in biotechnology, but also in medical devices and biopharmaceuticals, MPM has seamlessly integrated private and public equity products to target innovation in healthcare and, thereby, deliver exceptional returns to investors. The MPM BioVentures and MPM BioEquities family of funds are two distinctly different but highly complementary investment vehicles. |
National
Institutes of Health The NIH Office of Technology Transfer (OTT) evaluates, protects, monitors, and manages the NIH invention portfolio to carry out the mandates of the Federal Technology Transfer Act of 1986. This is largely accomplished through overseeing patent prosecution, negotiating and monitoring licensing agreements, and providing oversight and central policy review of Cooperative Research and Development Agreements. OTT also manages the patent and licensing activities for the Food and Drug Adminstration (FDA). OTT is responsible for the central development and implementation of technology transfer policies for four research components of the PHS — the NIH, the FDA, and the Centers for Disease Control and Prevention, and the Agency for Healthcare Research and Quality. |
NIB
Capital Private Equty NIBCapital Bank has the ambition to become one of the leading independent Merchant Banks in Northwestern Europe with a worldwide distribution network. The strong AA rating, the financially strong and committed shareholders ABP and PGGM and the compact organisation make for a uniquely positioned bank. The most important activities are corporate finance, risk management and structured investment solutions. The client focus is reflected in a platform of Client Sector Teams. A strong personal commitment to clients and teamwork are anchored in a multidisciplinary approach of product- and sector specialists. This leads to appropriate custom-made solutions in teams for our clients. The partnership structure and the high level of professionalism translates back in creativity and quality. The bank focuses on corporates, financial institutions, institutional investors and family offices. |
 |
Nomura Nomura’s biotech and healthcare research team provides extensive coverage for many of Europe's Mediscience companies. Mediscience is a broadly categorised group of lifescience or health-related companies that have the potential to grow rapidly. This diverse group of small to mid-cap companies includes biotechnology, healthcare, medical device, medical technology and medical services company sectors across Europe with a prime focus on the UK. The team specialises in identifying key industry themes across the world from a top down view. We then investigate individual companies that could benefit from these themes using a bottom-up view. We look for individual companies that are fundamentally undervalued, primarily based on risk adjusted net present value estimates of cash flow. In these very subjective areas, we also pay particular attention to relative valuations such as comparative analysis and non-numerical risk factors such as management and competition in drug specific areas. Nomura's team has a long established and externally recognised track record in these sectors: number one for the last three years in the Reuters smaller companies survey, according to both fund managers and finance directors. Individual responsibilities have evolved into the following broad categories. |
 |
Novartis
Institutes for BioMedical Research Profile available shortly. |
Oxford
Bioscience Partners Oxford Bioscience Partners (OBP) is a life science venture capital firm that provides equity financing and management assistance to start-up and early-stage, entrepreneurial-driven companies in the bioscience and healthcare industries. The General Partners of OBP currently manage venture funds with combined committed capital of more than $800 million. |
Pfizer
Global R&D Profile available shortly. |
 |
Polaris
Venture Partners Polaris Venture Partners is an early stage venture capital firm with two locations in the U.S: Boston, Massachusetts, and Seattle, Washington. Polaris currently has over $2.0 billion under management with investments in more than 50 diversified information technology and medical technology companies. Through its philosophy of active lead investing and partnering with early and revenue stage companies, the firm’s team of experienced venture investors and technology executives has generated triple-digit returns from investments across its four funds. Polaris invests two-thirds of its capital in information technology and one-third in medical technology companies. Within the information technology sector, Polaris has invested in companies with expertise in Internet infrastructure, e-commerce, telephony, and network hardware and software. In the medical technology sector, the firm has invested in companies focused on medical devices, pharmaceuticals, genomics, and health care services. Polaris Venture Partners has more than 50 companies in its portfolio, including industry leaders such as Akamai Technologies, Allaire Corporation, Avici, decode Genetics, and Paradigm Genetics. Headquarters: 1000 Winter Street, Suite 3350 |
Schroder
Ventures Life Sciences Schroder Ventures Life Sciences ("SVLS") was established in 1993 and currently has offices in Boston, London and San Francisco, which allows us to take advantage of the global nature of life sciences opportunities. The SVLS team is comprised of 24 professionals, with a deep base of life science investment, operational, scientific and clinical experience. SVLS advises three private equity funds with total commitments of approximately $640m, focused on providing seed, start-up, early stage and expansion capital to life sciences companies primarily in the US and Europe. In addition, SVLS advises the International Biotechnology Trust (IBT) plc, a publicly quoted investment trust listed on the London Stock Exchange (IBT), with a total net asset value of approximately $56m (as at 30 June 2002). The majority of IBT's investments are in quoted companies. Funds advised by SVLS are able to invest in all stages in the development of a life science business. SVLS provides hands-on scientific, advisory and financial support to its portfolio companies. |
|
SG Cowen Securities Corporation Profile available shortly. |
 |
Sofinnova
Partners Sofinnova Partners is a leading European venture capital firm dedicated to investing in early stage companies in Life Sciences and Information Technologies. Founded in Paris in 1972, Sofinnova Partners has been a fully independent partnership since 1997. We have € 500 million of active funds under management, including : Sofinnova Capital II (1994), a € 47 million fund ; Sofinnova Capital III (1998), a € 120 million fund ; Sofinnova Capital IV (closed in March 2001), a € 330 million fund. Our target for Sofinnova Capital IV is to invest in 30 ambitious technology start-up companies. We expect that Sofinnova Capital IV’s investments will be balanced between the life sciences and IT sectors, with 50%of the fund invested in France and 50% in the rest of Europe and the US. Life sciences sector For more information, please visit www.sofinnova.fr |
 |
Womble
Carlyle Sandridge & Rice, PLLC Founded in 1876, Womble Carlyle Sandridge & Rice, PLLC has a 127-year history of helping business leaders address evolving challenges and uncover new opportunities. One of the fastest growing law firms in the United States, Womble Carlyle has more than 450 lawyers and specialized professionals serving clients worldwide from offices located in Washington, DC; Northern Virginia; London (UK), Research Triangle Par; Atlanta; and other offices throughout the southeastern United States. The Firm’s Life Science practice represents one of its most dynamic and diversified groups, serving both national and international pharmaceutical, biotech, and other drug development and medical device companies, health care and managed care providers, related information technology companies, venture capital firms and equity funds. The Firm’s BioAlliance Practice, a unique, multi-disciplinary, industry-oriented group, provides bio-pharma clients with legal and related business development expertise for their corporate partnering activities. The Firm’s Technology & Commerce Group, comprised of over 80 intellectual property attorneys, includes over 40 patent prosecution lawyers and, together, with another 30 specialized litigators, handle sophisticated infringement litigation and an increasing number of licensing disputes for clients worldwide. Womble Carlyle also represents businesses, agencies and foundations in other industry sectors including financial services, telecommunications, software, manufacturing, transportation, energy, government relations, construction, and education. The legal community, and particularly the healthcare industry, has recognized Womble Carlyle for its innovative use of information technology, designed to facilitate the delivery of legal services and provide alternative solutions for improving management efficiencies and profitability. |
 |